5-Amino-1MQ
Also referenced as: 5-amino-1-methylquinolinium, NNMT inhibitor
A small-molecule NNMT inhibitor discussed alongside peptides, with no human evidence base.
- Evidence grade
- DPreclinical Research
Preclinical Research
- Regulatory status
- Research Use Only
- Human data
- No
No registered clinical trials identified
- Last reviewed
- September 1, 2026
Overview
Despite being grouped with peptides in consumer discussion, 5-Amino-1MQ is a small molecule, not a peptide. It inhibits nicotinamide N-methyltransferase (NNMT), an enzyme involved in NAD+ salvage and adipocyte metabolism.
All meaningful data are preclinical. Marketing language about metabolic transformation is not supported by human research.
Why It's Being Studied
- NNMT's role in adipose tissue metabolism and NAD+ availability.
- Whether NNMT inhibition alters fat mass in metabolic disease models.
Mechanism of Action
It blocks an enzyme that consumes a molecule cells use for energy metabolism, which in animals shifted how fat cells behaved.
NNMT methylates nicotinamide, diverting it from NAD+ salvage. Inhibition raises intracellular nicotinamide and NAD+ in adipocytes and has been associated in rodent models with reduced adipose tissue mass and altered lipogenic gene expression.
The incretin signalling pathway
Tap each stage to see what happens.
Background: Metabolic Health & Weight Management
Metabolic peptide research centres on the gut–brain–pancreas axis: hormones released after meals (incretins such as GLP-1 and GIP) that shape insulin release, stomach emptying and appetite.
This is the most clinically mature corner of peptide science. Several incretin-based medicines have large randomised trials behind them, which makes the gap between approved drugs and unapproved research compounds especially important to understand.
Research Areas & Routes Studied
- Adipose metabolism
- NAD+ biology
- Oral (in animal research)
Evidence Summary
Rodent and cell studies only. No published human clinical trials were identified at last review.
Higher tiers carry more weight. Filled tiers have evidence for 5-Amino-1MQ; tap to read it.
- Diet-induced obesity models reported reduced fat mass with NNMT inhibition.
1 cited sources.
- Animal study1
Animal studies
- Diet-induced obesity models reported reduced fat mass with NNMT inhibition.
In-vitro studies
- Adipocyte studies characterised NNMT inhibition and NAD+ changes.
Anecdotal / community information
- Community claims about weight loss and muscle preservation have no human trial support. No established human dosing protocol exists.
Reported Adverse Events in Research
- No human safety data. Adverse effects in people are unknown rather than absent.
Limitations of Current Evidence
- Preclinical only; rodent adipose biology translates unreliably to humans.
- Product identity and purity in the research-use-only market are frequently undocumented.
How to Read This Research
- Was weight loss measured against placebo, and over how many weeks?
- How much of the lost weight was lean mass rather than fat?
- What happened after the compound was stopped?
- Were cardiovascular, kidney or liver outcomes measured — or only weight?
- Percentage body-weight change versus placebo is the headline trial metric; absolute kilograms depend on starting weight.
- Gastrointestinal side effects are dose-related and usually reported by escalation phase.
- Compare approved-drug trial data with unapproved compounds carefully — a shared receptor is not shared evidence.
- Incretin
- A gut hormone that increases insulin release after eating.
- HbA1c
- A blood marker of average glucose over roughly three months.
- Agonist
- A molecule that activates a receptor.
Compare With Other Compounds
| 5-Amino-1MQ | Semaglutide | |
|---|---|---|
| Evidence grade | D — Preclinical Research | A — Strong Clinical Evidence |
| Regulatory status | Research Use Only | FDA Approved for Specific Indication |
| Human data | No | Yes |
| Clinical trials | None identified | Registered trials exist |
| Research routes | Oral (in animal research) | Subcutaneous injection, Oral tablet (approved form) |
| Cited sources | 1 | 4 |
Frequently Asked Questions
Why It Is Used
- Metabolic Health
Visceral Fat and Metabolic Markers
Not weight on a scale, but the fat around the organs — the compartment most strongly tied to metabolic risk.
Read the case study
Research References
- Animal study
Small molecule NNMT inhibition and adipose tissue metabolism